Are EGFR Tablets Like Gefitinib — Actually Chemotherapy?

Hair loss is not an expected side effect of gefitinib or other EGFR-targeted tablets. Hair loss happens with chemotherapy because it attacks rapidly dividing cells, including those in hair follicles. Gefitinib works differently and does not target cells in this way. Some people notice mild thinning, but significant hair loss of the kind associated with chemotherapy is not expected. If you are noticing unexpected hair changes, tell your team at your next appointment — there may be another explanation worth looking into.

EGFR-targeted tablets are intended to work in cancers that carry the specific mutation they target. Without that mutation, the cancer is not dependent on the EGFR signal in the same way, and these medicines are unlikely to help. This is why biopsy testing is done before treatment starts. If you are unsure whether your tissue was tested for EGFR mutation, ask your oncologist directly — the answer is usually in your pathology report and you are entitled to understand what it shows.

A mild rash is common and manageable with moisturisers and the skin-care advice your team gives you. If the rash becomes painful, starts to blister, looks infected, or covers a large area of your face or body, call your oncology team the same day rather than waiting for your next scheduled appointment. Do not apply any cream or antibiotic without checking first, as some products can worsen the rash or interact with the treatment. Your team will have a specific plan for managing severe skin reactions on EGFR tablets.

Your oncologist decides how long treatment continues based on how your cancer is responding and whether side effects are manageable. EGFR-targeted tablets are usually taken continuously rather than in cycles, which differs from many chemotherapy regimens. Treatment continues as long as the cancer is responding and benefits outweigh side effects. If the cancer changes and stops responding over time, your oncologist will reassess and discuss the next step with you. There is no fixed duration set in advance.

Some lung cancers develop changes over time that allow them to grow again despite the medicine — a process called acquired resistance. If this happens, your oncologist will usually arrange a repeat biopsy or a liquid biopsy to find out what has changed in the cancer. Depending on the result, a different EGFR inhibitor, a different class of treatment, or a combination may be an option. We do not yet fully understand how to prevent resistance, but identifying the mechanism when it occurs guides the next decision.

CION treats lung cancer across its centres in Telangana and Andhra Pradesh, and the decision about which medicine is right for you is made by your treating oncologist based on your biopsy results and overall situation. Targeted therapy, where indicated, is administered as day care. Biomarker testing to establish whether you carry an EGFR mutation is coordinated as part of your work-up. CION does not provide CAR-T or cell therapy; if that is ever discussed for you, you would be referred to a centre that offers it.